ExSight Ventures
VC Fund
New York, United States
ExSight Ventures is a venture capital firm specializing in early-stage impact investments in innovative ophthalmic diagnostic and treatment solutions. The firm consists of 2 accomplished retinal surgeons and a team of investment professionals that have partnered to address the need for funding early-stage ophthalmic-focused companies. The firmseeks investments in biotechnology, medical devices, pharmaceuticals and software solutions in ophthalmology.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries ExSight Ventures invests in
Health CareTherapeuticsBiotechnologyMedicalPharmaceutical
Stages ExSight Ventures invests in
Series ASeries BSeedSeries C
Countries ExSight Ventures invests in
United StatesUnited Kingdom
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adam Benowitz
|
|||
Alan Spiro
|
|||
James Murray
|
|||
Randolph Cohen
|
|||
Firas Rahhal
|
|||
| See all 7 contacts → | |||
Investment Focus
Industry
- Health Care 6 (30%)
- Therapeutics 6 (30%)
- Biotechnology 5 (25%)
- Medical 4 (20%)
- Pharmaceutical 3 (15%)
Stage
- Series A 6 (30%)
- Series B 4 (20%)
- Seed 3 (15%)
- Series C 1 (5%)
Country
- United States 9 (45%)
- United Kingdom 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Adam Benowitz
Partner
|
Partner | Total investments: 0 | Find email | |
|
Alan Spiro
Partner
|
Partner | Total investments: 0 | Find email | |
|
James Murray
Partner & Co-Founder
|
Partner & Co-Founder | Total investments: 2 | Find email | |
|
Randolph Cohen
Partner
|
Partner | Total investments: 0 | Find email | |
|
Firas Rahhal
Partner
|
Partner | Total investments: 5 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DefEYE
|
DefEYE's vision is to improve eye health by providing novel, comprehensive therapeutic and diagnostic solutions that establish a new standard of treatment for ocular disease. | $12M / Seed / Oct 30, 2025 | |
RevOpsis Therapeutics
|
RevOpsis Therapeutics has directed its efforts towards addressing vision loss. By utilizing their exclusive bispecific Surrobody platform, the company aims to target a diverse range of ocular conditions with potential therapeutic agents. The company was founded in 2022 and is based in Springfield, Illinois, United States. | Seed / Sep 16, 2025 | |
Horizon Surgical Systems
|
Horizon Surgical Systems specializes in the development of innovative technologies for microsurgery, focusing on robotics, medical imaging, and artificial intelligence. The company is dedicated to transforming the field of surgical ophthalmology by creating a novel, AI-driven, and imaging-guided surgical robotic system. This initiative aims toenhance the precision and effectiveness of microsurgical procedures, thereby improving patient outcomes. Horizon Surgical Systems is actively engaged in research and development to push the boundaries of what is possible in microsurgery, leveraging the latest advancements in technology to meet the evolving needs of healthcare professionals and patients. | $30M / Series A / Oct 16, 2024 | |
|
Horizon Surgical Systems
|
Horizon Surgical Systems specializes in the development of innovative technologies for microsurgery, focusing on robotics, medical imaging, and artificial intelligence. The company is dedicated to transforming the field of surgical ophthalmology by creating a novel, AI-driven, and imaging-guided surgical robotic system. This initiative aims toenhance the precision and effectiveness of microsurgical procedures, thereby improving patient outcomes. Horizon Surgical Systems is actively engaged in research and development to push the boundaries of what is possible in microsurgery, leveraging the latest advancements in technology to meet the evolving needs of healthcare professionals and patients. | $30M / Series A / Oct 16, 2024 | |
ONL Therapeutics
|
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $15M / Series C / Mar 08, 2023 | |
Re-Vana Therapeutics
|
Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and ocular infections.Their deliveryplatforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using their platform technologies, delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 1 week to 1 year. The platform technologies are based on FDA-approved polymers.Their injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months. Their preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 6 months or more.The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies. | $12.1M / Series A / Nov 30, 2022 | |
|
Re-Vana Therapeutics
|
Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and ocular infections.Their deliveryplatforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using their platform technologies, delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 1 week to 1 year. The platform technologies are based on FDA-approved polymers.Their injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months. Their preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 6 months or more.The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies. | $12.1M / Series A / Nov 30, 2022 | |
|
Re-Vana Therapeutics
|
Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and ocular infections.Their deliveryplatforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using their platform technologies, delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 1 week to 1 year. The platform technologies are based on FDA-approved polymers.Their injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months. Their preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 6 months or more.The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies. | $12.1M / Series A / Nov 30, 2022 | |
Valitor
|
Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Their technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. They currentlyhave three development pipelines in the fields of dermatology, ophthalmology, and orthopedics that highlight the capabilities of their novel drug products. | $28M / Series B / Oct 05, 2022 | |
DTx Pharma
|
DTx Pharma develops technology that will unleash RNA-based therapeutics as the modality of choice for personalized treatment across therapeutic areas. DTx Pharma believes its approach to delivering RNA medicines solves some of the issues that limited previous-generation platforms, including poor pharmacokinetics and insufficient cellular uptake. | $100M / Series B / Mar 01, 2021 | |
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does ExSight Ventures invest in?
ExSight Ventures invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Series B stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact ExSight Ventures?
Public channels for ExSight Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ExSight Ventures?
The team at ExSight Ventures includes Adam Benowitz (Partner), Alan Spiro (Partner) and James Murray (Partner & Co-Founder), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
